About 12 results found for searched term "PLK1-IN-5" (0.487 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M41581 | PLK1-IN-5 | PLK |
| PLK1-IN-5 is a potent PLK1 inhibitor with an IC50 of < 500 nM. | ||
| M1672 | BI 2536 | PLK |
| BI 2536 is a novel, highly selective, potent dual PLK1 and BRD4 inhibitor with IC50s of 0.83 and 25 nM, respectively. | ||
| M2860 | MLN0905 | PLK |
| PLK1 Inhibitor | ||
| MLN0905 is an orally active, potent PLK1 inhibitor with an IC50 of 2 nM. can be used in tumor related studies. | ||
| M3198 | TAK-960 | PLK |
| TAK-960 is a novel, potent and selective Plk1 inhibitor with IC50 of 8 nM. | ||
| M7350 | TAK 960 hydrochloride | PLK |
| TAK 960 hydrochloride is a potent PLK1 inhibitor (IC50 values are 0.8, 16.9 and 50.2 nM for PLK1, PLK2 and PLK3 respectively). Exhibits >20-fold selectivity for PLK1 over FAK, MLCK and FES, and has minimal activity against a panel of 282 other kinases. | ||
| M13718 | Onvansertib | PLK |
| PCM-075; NMS-1286937; NMS-P937 | ||
| Onvansertib (PCM-075, NMS-1286937, NMS-P937) is a first-in-class, third-generation, oral, highly selective PLK1 inhibitor that induces tumor cell arrest in the G2/M phase and triggers apoptosis. It has a median IC50=136nM against a variety of CRC cell lines and inhibits xenograft models such as HT-29, HCT-116, and Colo-205 well. | ||
| M29436 | AAPK-25 | Aurora Kinase |
| AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in a prometaphase, reflecting by the biomarker histone H3Ser10 phosphorylation and followed by a surge in apoptosis. AAPK-25 targets Aurora-A, -B, and -C with Kd values ranging from 23-289 nM, as well as PLK-1, -2, and -3 with Kd values ranging from 55-456 nM. | ||
| M30051 | Cyclapolin 9 | PLK |
| Cyclapolin 9 is a potent, selective and ATP-competitive polo-like kinase 1 (PLK1) inhibitor with an IC50 of 500 nM. Cyclapolin 9 is inactive against other kinases. | ||
| M38942 | Dihydrobaicalein | PLK |
| Dihydrobaicalein is a PLK1 Inhibitor with an IC50 of 6.3 μM. Dihydrobaicalein also inhibits VRK2 and PLK2. Dihydrobaicalein is a natural product that can be isolated from Scutellaria scandens. | ||
| M41580 | PLK1-IN-6 | PLK |
| PLK1-IN-6 is a potent and selective PLK1 inhibitor, with an IC50 of 0.45 nM. | ||
| M49473 | Plogosertib | PLK |
| CYC140 | ||
| Plogosertib is a selective, potent, orally active, ATP-competitive PLK1 inhibitor with an IC50 value of 3 nM.In addition, Plogosertib exhibits antiproliferative and anticancer activity and can be used in a variety of tumor studies. | ||
| M49490 | 3MB-PP1 | PLK |
| 3MB-PP1 is a bulky purine analog and inhibitor of Polo-like kinase 1 (Plk1) that blocks mitotic progression and cytokinesis by targeting Plk1 in cells expressing the analog-sensitive Plk1 allele. 3MB-PP1 also specifically inhibits the activity of Leu93 mutant Zipper-interacting Ssn3 (Cdk8). 3MB-PP1 inhibits the activity of Leu93 mutant Zipper-interacting Ssn3 (Cdk8). In addition, 3MB-PP1 specifically inhibits the activity of analog-sensitive Ssn3 (Cdk8). 3MB-PP1 inhibits the Leu93 mutant Zipper-interacting protein kinase (Leu93-ZIPK; IC50=2 μM). 3MB-PP1 can be used in the mycelium of Candida albicans. 3MB-PP1 can be used in studies related to mycelium formation and cell division in Candida albicans. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
